Natco Pharma Reports Q1 FY27 Results; Declares Interim Dividend and Explores Up to ₹2000 Crore Fund Raising
Hyderabad: NATCO Pharma Limited has announced its consolidated results for the first quarter of financial year 2027, alongside declaring an interim dividend. The company also disclosed that its Board is evaluating options for future fundraising up to INR 2000 Crores.The company reported consolidated total revenue of INR 794.4 Crore for the quarter ended June 30, 2026. This figure compares against INR 1,390.6 Crore from the corresponding quarter in the previous year. The net profit on a consolidated basis was INR 206.5 Crore, down from INR 480.3 Crore in the prior year's corresponding period.
Strategic Updates and Shareholding Gains
NATCO Pharma’s associate company, Adcock Ingram Holdings Limited in South Africa, generated revenue of INR 1,582.8 crores for the quarter, with a profit after tax reported at INR 242.2 crores. NATCO's share of this associate's profit stood at INR 84.3 crores, based on its holding of 35.75% as of June 30, 2026. The company subsequently acquired an additional 13.25% stake in Adcock Ingram Holdings Limited in July 2026, raising the total holding to 49%.In response to the quarterly performance, the Board of Directors approved an interim dividend of INR 1.5 per equity share of INR 2 each for Q1 FY27.
Segment Performance Overview (INR Crore)
The company segmented its operations across various business units. The sectoral breakdown reveals as follows:| Business Segments | Q1 FY27 | Q1 FY26 |
|---|---|---|
| Active Pharmaceutical Ingredients (API) | 66.7 | 52.6 |
| Domestic Pharmaceutical Formulations | 136.4 | 107.0 |
| International Formulations (Incl. profit share and subsidiaries) | 477.1 | 1,120.9 |
| Crop Health Sciences (CHS) | 40.8 | 34.7 |
| Other operating and non-operating income | 73.4 | 75.4 |
| Total | 794.4 | 1,390.6 |
Corporate Governance and Future Capital Plans
The Board of Directors also approved the evaluation and exploration of raising funds through various methods, including public issues, preferential issues, rights issues, private placement(s), qualified institutions placement(s), or any combination thereof. This potential fundraising is capped at an amount not exceeding INR 2000 Crores.Furthermore, the Board approved the reconstitution of the Risk Management Committee and the Environment, Social and Governance Committee effective August 14, 2026. The company also approved the notice for its 43rd Annual General Meeting.
NATCOPHARM Stock Price Movement
Shares of Natco Pharma Limited slipped on Friday, shedding 5.65% to close at ₹897.95 after trading significantly below its previous closing price. The stock saw trading volumes reach 2.06 million shares during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.